The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Amarin | Spons ADR | 023111206 | 14,638 | 8,087,486 | SH | DFND | 8,087,486 | 0 | 0 | ||
Anthera | Common | 03674U102 | 1,467 | 437,994 | SH | DFND | 437,994 | 0 | 0 | ||
Cempra | Common | 15130J109 | 8,243 | 714,285 | SH | DFND | 714,285 | 0 | 0 | ||
Dicerna | Common | 253031108 | 33,314 | 1,182,196 | SH | DFND | 1,182,196 | 0 | 0 | ||
GW Pharma (US) | Spons ADR | 36197T103 | 6,067 | 102,200 | SH | DFND | 102,200 | 0 | 0 | ||
Hyperion | Common | 44915N101 | 1,612 | 62,500 | SH | DFND | 62,500 | 0 | 0 | ||
Oncogenex Pharma | Common | 68230A106 | 7,088 | 603,740 | SH | DFND | 603,740 | 0 | 0 | ||
Portola | Common | 737010108 | 32,140 | 1,240,912 | SH | DFND | 1 | 1,240,912 | 0 | 0 | |
Prosensa | Common | N71546100 | 34,860 | 6,213,924 | SH | DFND | 1 | 6,213,924 | 0 | 0 | |
Regulus | Common | 75915K101 | 2,943 | 327,350 | SH | DFND | 327,350 | 0 | 0 | ||
Supernus | Common | 868459108 | 32,148 | 3,600,000 | SH | DFND | 1 | 3,600,000 | 0 | 0 | |
Zalicus | Common | 98887C105 | 96 | 78,966 | SH | DFND | 78,966 | 0 | 0 | ||
Zogenix | Common | 98978L105 | 6,632 | 2,335,218 | SH | DFND | 1 | 2,335,218 | 0 | 0 |